Fresenius Medical Care AG & Co. (FMS) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a hold rating to a buy rating in a research note released on Monday, January 8th. Zacks Investment Research currently has $61.00 price target on the stock.

According to Zacks, “Fresenius has had a disappointing run on the bourse over the last six months. However, a solid full-year guidance instills our confidence on the stock. We believe this is in tune with the ‘Growth Strategy 2020’, under which it aims to boost revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. A wide range of dialysis products, initiatives to gain market traction, strengthened international foothold, strategic acquisitions and divestments act as major catalysts.On the flipside, lackluster performance by the renal pharmaceutical segment is likely to dent Latin-American revenues in the coming quarters. Having a strong international foothold, Fresenius faces the brunt of stringent regulations in almost every country in which it operates. Thus, it has to fulfill specific legal requirements that include tough antitrust laws. Regulatory hurdles and competition in the niche markets are major headwinds.”

FMS has been the topic of several other research reports. Nord/LB reaffirmed a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Tuesday, January 2nd. UBS Group raised shares of Fresenius Medical Care AG & Co. from a sell rating to a neutral rating in a research report on Thursday, January 4th. DZ Bank reaffirmed a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, December 18th. Morgan Stanley lowered shares of Fresenius Medical Care AG & Co. from an overweight rating to an equal weight rating in a research report on Monday, December 11th. Finally, SunTrust Banks set a $62.00 price objective on shares of Fresenius Medical Care AG & Co. and gave the stock a buy rating in a research report on Thursday, December 21st. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $55.67.

Fresenius Medical Care AG & Co. (NYSE FMS) traded down $0.06 on Monday, hitting $54.47. 104,293 shares of the company were exchanged, compared to its average volume of 153,310. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.22 and a quick ratio of 0.98. Fresenius Medical Care AG & Co. has a one year low of $40.02 and a one year high of $55.30. The company has a market capitalization of $33,510.00, a price-to-earnings ratio of 21.88, a P/E/G ratio of 2.27 and a beta of 0.45.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.02). Fresenius Medical Care AG & Co. had a net margin of 7.04% and a return on equity of 11.51%. analysts predict that Fresenius Medical Care AG & Co. will post 2.37 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. UBS Asset Management Americas Inc. increased its stake in shares of Fresenius Medical Care AG & Co. by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after purchasing an additional 81 shares in the last quarter. Pacer Advisors Inc. purchased a new position in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $179,000. HPM Partners LLC purchased a new position in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $221,000. YorkBridge Wealth Partners LLC increased its stake in shares of Fresenius Medical Care AG & Co. by 19.4% in the second quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after purchasing an additional 749 shares in the last quarter. Finally, Stifel Financial Corp purchased a new position in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $225,000. 3.03% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Fresenius Medical Care AG & Co. (FMS) Raised to Buy at Zacks Investment Research” was originally reported by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://baseballnewssource.com/markets/fresenius-medical-care-ag-co-fms-upgraded-by-zacks-investment-research-to-buy/1821634.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.